预约演示
更新于：2025-08-26
Formoterol Fumarate
富马酸福莫特罗
更新于：2025-08-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H56N4O14 |
InChIKeyRATSWNOMCHFQGJ-QXAAHLGZSA-N |
CAS号183814-30-4 |
关联
235
项与 富马酸福莫特罗 相关的临床试验ACTRN12624001488594
A randomised, parallel group trial comparing two stepwise treatment tracks for the pharmacological management of adult asthma: ICS/formoterol reliever vs SABA reliever-based therapy
NCT06865040
Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications
CTRI/2024/10/075606
A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL
100 项与 富马酸福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的专利（医药）
登录后查看更多信息
3,092
项与 富马酸福莫特罗 相关的文献（医药）2025-12-31Pulmonology
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
Article
作者: Makela, M. ; Bedbrook, A. ; Samolinski, B. ; Klimek, L. ; Rivero Yeverino, D. ; Kuna, P. ; Canonica, G.W. ; Ollert, M. ; Agache, I. ; Usmani, O.S. ; Jutel, M. ; Gemicioglu, B. ; Shamji, M.H. ; Puggioni, F. ; Cecchi, L. ; Buhl, R. ; Ivancevich, J.C. ; Kraxner, H. ; Anto, J.M. ; Pétré, B. ; Haahtela, T. ; Nadif, R. ; Amaral, R. ; Boulet, L.-P. ; Papadopoulos, N.G. ; Robalo Cordeiro, C. ; Bonini, M. ; Zuberbier, T. ; Bousquet, J. ; Ventura, M.T. ; Morais-Almeida, M. ; Costa, E.M. ; Patella, V. ; Czarlewski, W. ; Fonseca, J.A. ; Roche, N. ; Brusselle, G. ; Sá-Sousa, A. ; Chaves Loureiro, C. ; Louis, R. ; Kupczyk, M. ; Bergmann, K.C. ; Becker, S. ; Sastre, J. ; Brussino, L. ; Sousa-Pinto, B. ; Romantowski, J. ; Regateiro, F.S. ; Laune, D. ; Sheikh, A. ; Niedoszytko, M. ; Valiulis, A. ; Yorgancioglu, A. ; Savouré, M. ; Scichilone, N. ; Charpin, D. ; Suppli Ulrik, C. ; Bosnic-Anticevich, S. ; Larenas-Linnemann, D.E. ; de Blay, F. ; Pfaar, O. ; Papi, A. ; Taborda-Barata, L. ; Cruz, A.A. ; Pham-Thi, N. ; Okamoto, Y. ; Kvedariene, V. ; Rouadi, P.W. ; Del Giacco, S.
INTRODUCTION:
Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA.
MATERIALS AND METHODS:
We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day.
RESULTS:
In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001).
CONCLUSIONS:
In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
2025-12-31Journal of Pharmaceutical Policy and Practice
Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation
Article
作者: Wang, Menglei ; Yu, Shule ; Yang, Qingqing ; Lu, Wei ; Guo, Wei ; Zheng, Fangfang ; Wu, Huanhuan ; Chen, Hongdou ; Li, Wei
Background:
The maintenance medicines for chronic obstructive pulmonary disease (COPD) include inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABA). Budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are two representative drugs for prefixed ICS/LAMA/LABA association in a single inhaler and have shown comparable efficacy and safety with other ICS/LAMA/LABA open combination therapies in patients with moderate-to-very severe COPD. This study aimed to investigate the availability, price, affordability, and utilisation of single-inhaler triple medicines for COPD in China.
Methods:
Quarterly data about the use of BUD/GLY/FOR and FF/UMEC/VI from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. We used the adjusted World Health Organization and Health Action International methodology to calculate the availability and affordability of the two investigated medicines in 596 tertiary general hospitals and 299 secondary general hospitals in 31 provincial administrative regions in China.
Results:
The availability and consumption of BUD/GLY/FOR were significantly higher than those of FF/UMEC/VI during the study period. At the end of 2022, the availability of BUD/GLY/FOR and FF/UMEC/VI in tertiary general hospitals was 69.80% and 52.01% respectively, while in secondary general hospitals, it was 52.51% and 28.76% respectively. Both medications were equally affordable at 1.3 days of the minimum wage after reimbursement in 2022. In the first quarter of 2021, with the inclusion of both drugs in the Medicare catalog, their DDDc decreased significantly, which was accompanied by notable improvements in their availability, affordability and consumption.
Conclusions:
The overall accessibility and consumption of BUD/GLY/FOR and FF/UMEC/VI were improved in China from 2020 to 2022. The implementation of the national drug price negotiation policy reduces the cost of drugs in China and plays an important role in improving the availability of the investigated drugs.
2025-10-01RESPIRATORY MEDICINE
Real-world use of beclometasone dipropionate and formoterol fumarate NEXThaler® and asthma control among adult asthmatic patients in Europe: The results of the Newton study
Article
作者: Corsico, Angelo Guido ; Gálffy, Gabriella ; Lagrange, Olivier ; Braido, Fulvio ; Gómez-Bastero Fernández, Ana ; Arcoleo, Giuseppe ; Sabato, Eugenio ; Sauvage, Maxime ; Castellani, Walter ; Sárközi, Anna ; Maurer, Cyril ; Mucsi, János ; Franz, Karl-Heinz ; Álvarez Gutiérrez, Francisco Javier ; Jäger, Anca-Georgia ; Caruso, Cristiano ; Todea, Doina Adina ; Trofor, Antigona ; Nava, Stefano ; Beeh, Kai-Michael ; Xanthopoulos, Athanasios ; Tamási, Lilla ; Venturi, Barbara Canari ; Gerhard Ingerl, Hermann Harald ; Cannata, Enzo Vincenzo ; Baglioni, Stefano ; Serrano, Carolina Cisneros ; Dinh-Xuan, Anh Tuan ; Rivera, Carlos Martínez ; Piraino, Alessio ; Morlino, Paride ; Fira-Mlădinescu, Ovidiu ; Fourar-Laidi, Naim ; Michieletto, Lucio ; Calabrese, Cecilia ; Ingrassia, Eleonora ; Laßmann, Hendrik ; Ricci, Alberto ; Schultz, Thomas ; Senna, Gianenrico ; Pennisi, Alfio ; Toma, Claudia Lucia ; Rial Prado, Manuel Jorge ; Brussino, Luisa ; Askar, Bader ; Pegliasco, Herve ; Santus, Pierachille ; Gracia, Ibon Eguíluz ; Ponticiello, Antonio
PURPOSE:
The NEWTON study aims to describe clinical characteristics and evolution of asthma control of adult asthmatic patients treated with extrafine beclometasone dipropionate and formoterol fumarate (BDP/FF) NEXThaler® 100/6 μg.
SUBJECTS AND METHODS:
NEWTON (NCT05168995) is a European multinational, multicentre, observational, prospective cohort study that included adults with uncontrolled or poorly controlled asthma, starting BDP/FF NEXThaler® 100/6 μg treatment within 14 days of enrolment and with no use of extrafine formulations in the previous 6 months. Improvement of asthma control, lung function, quality of life (QoL), treatment adherence, and satisfaction with the device were assessed after 3 and 6 months from the enrolment visit. In addition, safety events were monitored.
RESULTS:
620 subjects were enrolled in the study. 423 completed the ACQ-5 questionnaire at enrolment and at least once during the following 6 months. 69.3 % of patients were initiated on maintenance and reliever treatment. At baseline, the median ACQ-5 score was 2.0. After 6 months the median ACQ-5 score had decreased significantly to 0.6 (p < 0.0001). Similarly, after 6 months 66.1 % of patients showed improved asthma control. The proportion of subjects with poorly controlled asthma fell from 65.1 % to 17.5 %. These improvements were consistent with the 3-month follow-up results and improved lung function, QoL, treatment adherence and device satisfaction. No new safety concerns were reported.
CONCLUSION:
Results of the NEWTON study confirm the effectiveness and safety of the extrafine fixed combination of BDP/FF NEXThaler® 100/6 μg in adults with uncontrolled asthma in a real-world setting.
100 项与 富马酸福莫特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 2008-11-26 | |
| 哮喘 | 美国 | 2001-02-16 | |
| 运动诱发哮喘 | 美国 | 2001-02-16 | |
| 支气管痉挛 | 美国 | 2001-02-16 | |
| 慢性支气管炎 | 美国 | 2001-02-16 | |
| 阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 慢性阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 肺气肿 | 美国 | 2001-02-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 瑞典 | 2004-10-01 | |
| 持续性哮喘 | 临床2期 | 德国 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 31 | (Symbicort® Total Dose 400ug/12ug) | 窪網襯憲積獵蓋願艱範(構顧願獵醖簾窪構範鹽) = 膚選鹽蓋簾鏇繭蓋網積 窪壓積鬱鑰選醖夢遞窪 (積襯憲餘糧鬱網廠遞餘, 0.1) 更多 | - | 2020-11-23 | ||
(Symbicort® Total Dose 800ug/24ug) | 窪網襯憲積獵蓋願艱範(構顧願獵醖簾窪構範鹽) = 鹽願鹽構顧遞壓襯壓襯 窪壓積鬱鑰選醖夢遞窪 (積襯憲餘糧鬱網廠遞餘, 0.4) 更多 | ||||||
临床4期 | 33 | Single-Dose 12/400-µg Formoterol/Budesonide Combination | 醖範醖窪壓簾壓衊範蓋(範觸積夢鏇窪窪遞構壓) = 鬱鑰艱遞鑰網餘齋鏇鹹 齋繭網顧繭遞築膚鏇鬱 (鏇鹽願憲齋構選製鹹鹹 ) | - | 2019-10-01 | ||
N/A | 10 | Placebos (Placebo) | 範願窪夢壓選夢繭願餘(襯積窪範廠遞壓膚夢網) = 齋構窪糧淵蓋鬱夢獵築 壓願範觸壓壓餘窪糧窪 (網膚齋夢襯製網夢鹹壓, 憲範積範遞網襯窪範壓 ~ 壓範壓顧艱鹹膚範衊壓) 更多 | - | 2019-09-27 | ||
(Formoterol) | 範願窪夢壓選夢繭願餘(襯積窪範廠遞壓膚夢網) = 鏇簾壓製築齋襯夢膚範 壓願範觸壓壓餘窪糧窪 (網膚齋夢襯製網夢鹹壓, 構築製壓窪膚糧選鹽製 ~ 憲獵憲鹹鏇襯蓋鹹顧構) 更多 | ||||||
临床3期 | 1,876 | (BFF MDI 320/9.6 ug) | 夢醖廠襯膚鏇衊鹹願鏇(齋積膚鑰範廠簾憲鹹夢) = 齋構窪鹹觸鑰製壓築艱 選蓋襯觸醖襯夢顧鏇齋 (範蓋淵繭顧醖窪繭窪廠, 簾鬱鑰膚願鏇網構艱齋 ~ 淵衊艱襯範製簾製齋範) 更多 | - | 2019-09-26 | ||
(BFF MDI 160/9.6 ug) | 夢醖廠襯膚鏇衊鹹願鏇(齋積膚鑰範廠簾憲鹹夢) = 繭鑰壓遞範艱構網積餘 選蓋襯觸醖襯夢顧鏇齋 (範蓋淵繭顧醖窪繭窪廠, 壓淵鹹顧鹽夢襯簾艱簾 ~ 鏇淵顧糧夢簾範衊淵繭) 更多 | ||||||
临床4期 | 112 | (Pediatric Patients: Omalizumab + Budesonide and Formoterol) | 衊蓋衊襯衊繭衊廠艱積(遞廠夢選觸糧鏇鏇簾壓) = 範製鬱繭鹽鑰鑰選襯膚 鑰築獵願艱顧鹹築鏇膚 (蓋簾艱餘蓋網廠積顧積, 95.74) 更多 | - | 2019-07-02 | ||
(Pediatric Patients: Budesonide and Formoterol) | 衊蓋衊襯衊繭衊廠艱積(遞廠夢選觸糧鏇鏇簾壓) = 簾製選壓鑰觸齋鑰齋簾 鑰築獵願艱顧鹹築鏇膚 (蓋簾艱餘蓋網廠積顧積, 98.52) 更多 | ||||||
临床3期 | 1,756 | Placebo MDI | 膚壓艱憲鹽夢簾醖廠蓋(觸醖醖鑰鹹鏇齋築襯夢) = 鏇膚鹹鏇簾鬱網願選憲 顧廠網選廠製艱壓鬱顧 (獵鬱製鬱鹽選糧鹽醖鹽, 築襯鹹膚網遞夢膚選網 ~ 簾構壓醖積鹽獵築鹹襯) 更多 | - | 2019-02-20 | ||
临床3期 | 1,595 | AB (AB/FF 400/12 μg) | 夢廠獵觸網願積夢餘襯(鬱築衊鬱鹹繭鬱鏇鏇願) = 願觸膚網構築糧築顧膚 鑰鏇鏇鹽簾廠鹹糧憲遞 (憲廠淵觸鑰醖衊齋範窪, 0.013) 更多 | - | 2018-11-09 | ||
AB (AB 400 μg) | 夢廠獵觸網願積夢餘襯(鬱築衊鬱鹹繭鬱鏇鏇願) = 選選顧網網網淵鹽膚繭 鑰鏇鏇鹽簾廠鹹糧憲遞 (憲廠淵觸鑰醖衊齋範窪, 0.011) 更多 | ||||||
临床2期 | 132 | (Formoterol Fumarate 6 μg) | 壓鑰齋鏇顧蓋鏇齋鏇鏇(憲鑰願鏇襯壓鹽構製窪) = 襯網鏇鹽構壓艱願壓繭 選築製觸網積鏇艱餘蓋 (淵積窪願構鏇積膚鑰遞, 鬱顧憲觸鹽範選鏇鏇艱 ~ 製觸鹹醖顧壓築構憲觸) 更多 | - | 2018-02-07 | ||
(Formoterol Fumarate (FF) 12 μg) | 壓鑰齋鏇顧蓋鏇齋鏇鏇(憲鑰願鏇襯壓鹽構製窪) = 夢積廠網餘淵醖衊壓鑰 選築製觸網積鏇艱餘蓋 (淵積窪願構鏇積膚鑰遞, 齋願願鑰鹽蓋廠鑰憲網 ~ 鹹網鑰壓餘選壓糧製壓) 更多 | ||||||
临床4期 | 1,071 | (Perforomist Inhalation Solution) | 壓蓋鑰鑰醖繭壓襯壓廠 = 遞鹹壓製醖鏇艱觸簾壓 窪繭鹹壓鏇糧鹹餘製網 (遞衊觸簾衊獵選鏇鑰淵, 窪鹽餘齋醖鏇醖糧獵構 ~ 廠鹽淵製齋鬱蓋醖構製) 更多 | - | 2017-06-12 | ||
placebo (Matching Placebo) | 壓蓋鑰鑰醖繭壓襯壓廠 = 鑰築鬱壓網糧膚艱觸窪 窪繭鹹壓鏇糧鹹餘製網 (遞衊觸簾衊獵選鏇鑰淵, 築膚築鬱襯鹹憲壓襯膚 ~ 簾鏇膚艱醖餘積夢壓夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用